Overview of adverse drug reaction reports

Adverse drug reaction reporting refers to the process of systematically recording and submitting harmful reactions that occur under normal usage and dosage of drugs and have nothing to do with the purpose of medication. Its main contents includeDefinition of adverse reactions, reporting entities, reporting process, regulatory significance and public participation. The core purpose is to ensure drug safety and provide a basis for drug risk management and control through timely collection and analysis of data. The reporting entities cover medical institutions, manufacturing enterprises, operating enterprises and individuals, among which medical institutions and manufacturing enterprises bear the main responsibility. The reporting process usually includes four steps: discovery, recording, evaluation and submission, and is finally summarized and analyzed by the drug regulatory department.

Definition and classification of adverse drug reactions

Adverse drug reactions (ADR) refer to harmful reactions that occur under normal usage and dosage of qualified drugs and have nothing to do with the therapeutic purpose, including side effects, toxic reactions, allergic reactions, etc. According to the severity, it can be divided intomild, moderate and severe, divided according to frequency of occurrencecommon, rare and very rare. For example, common adverse reactions may manifest as dizziness or gastrointestinal discomfort, while rare reactions may involve impairment of liver and kidney function. Clear classification helps to accurately assess risks and provides a standardized basis for subsequent reporting.

Reporting entities and legal responsibilities

According to the "Adverse Drug Reaction Reporting and Monitoring Management Measures",Medical institutions, pharmaceutical manufacturing companies and operating companiesIt is a legal reporting entity and must submit a report within 15 days after discovering adverse reactions. Serious cases must be reported immediately. Individuals can also make voluntary reports through the drug regulatory department’s official website or hotline. Companies that fail to fulfill their obligations may face penalties such as warnings and fines. For example, a pharmaceutical company was fined 100,000 yuan by the regulatory authorities for failing to report a severe allergic reaction to a certain antihypertensive drug in a timely manner, highlighting the importance of legal constraints.

Reporting process and data application

The reporting process includesDiscovery→Record→Preliminary Assessment→Submit→Regulatory Department Analysis. Medical institutions usually evaluate the causal relationship of adverse reactions through internal pharmaceutical committees and then submit them through the national adverse drug reaction monitoring system (such as China’s “sentinel hospital” network). Regulatory authorities use big data to identify risk signals and issue drug warnings or modify instructions when necessary. For example, the use of a certain antibiotic was restricted due to multiple reports of liver injury, which reflects the direct effect of data application.

Summary and the significance of public participation

Adverse drug reaction reporting is the cornerstone of the drug safety system, and early detection and early intervention of risks can be achieved through multi-party collaboration. Public participation can supplement cases not covered by medical institutions, such as patients self-reporting symptoms of rash or heart palpitations after taking medication. Regulatory authorities regularly publish "Adverse Drug Reaction Information Notices" to improve transparency. For example, the 2022 National Adverse Drug Reaction Monitoring Annual Report shows that anti-infective drugs account for the highest proportion of reports (28.5%), suggesting the need to focus on the risks of this type of drugs. The public can participate conveniently through the "Adverse Drug Reaction Direct Reporting System" WeChat applet.

Quote sources:
1. "Adverse Drug Reaction Reporting and Monitoring Management Measures" (State Administration for Market Regulation Order No. 29)
2. National Adverse Drug Reaction Monitoring Center's "2022 Annual Report on Adverse Drug Reaction Monitoring"
3. World Health Organization (WHO) "Pharmacovigilance in South Africa"
4. Examples of manufacturing companies:Hengrui Medicine(Product name: cyclophosphamide for injection),Tongrentang(Product name: Angong Niuhuang Pills)